India Pharma Outlook Team | Thursday, 21 May 2026
Dr Reddy’s launches oral semaglutide Obeda in India, expanding treatment options for people living with Type 2 diabetes and marking an important step in making advanced diabetes care more accessible.
The Hyderabad-based pharmaceutical company has introduced the once-daily oral medicine as a more convenient alternative for patients who prefer tablets over injectable treatments. The launch comes at a time when India continues to see a sharp rise in diabetes cases, increasing the demand for affordable and effective long-term treatment options.
The newly introduced Obeda tablets are available in three strengths — 3 mg, 7 mg, and 14 mg — and are designed for daily use under medical supervision. Dr Reddy’s has priced the medicine at ?99, ?135, and ?225 per tablet, depending on the dosage, in an effort to make the therapy accessible to a larger number of patients across the country.
Oral semaglutide belongs to a class of medicines known as GLP-1 receptor agonists, which help manage blood sugar levels in adults with Type 2 diabetes. Unlike injectable versions of semaglutide, Obeda offers patients a tablet-based option that may make treatment easier to follow. The medicine works by supporting insulin release, helping regulate blood sugar levels, and improving overall diabetes management when combined with proper diet and exercise.
Also Read: India Boosts Ebola Surveillance After WHO Global Emergency
The launch highlights Dr Reddy’s growing focus on therapies for diabetes and obesity treatment, particularly in the expanding GLP-1 treatment market. These medicines have gained strong attention globally because of their effectiveness in managing blood sugar and supporting weight control in some patients.
Industry experts say India’s pharmaceutical market is witnessing increased competition in semaglutide-based medicines after patent protections expired earlier this year. This has encouraged companies to introduce more affordable alternatives to premium branded products, improving patient access to modern therapies.
Dr Reddy’s has already expanded its semaglutide offerings through injectable versions in India and other international markets. With the addition of oral Obeda, the company is aiming to strengthen its presence in the metabolic disease treatment segment and provide patients with more treatment choices.
According to the company, Obeda received approval from the Central Drugs Standard Control Organisation (CDSCO) following a Phase III clinical study conducted in India involving 288 adults with Type 2 diabetes. The study reportedly showed results comparable to the original branded medicine in controlling blood sugar levels and reducing HbA1c levels, an important indicator used to monitor diabetes management.
Dr Reddy’s also stated that the medicine was developed and manufactured in-house, helping ensure quality and supply consistency. Company officials said the launch reflects their commitment to improving access to advanced diabetes care solutions for Indian patients.
As diabetes continues to affect millions across the country, affordable oral treatment options such as Obeda may help make blood sugar control and advanced diabetes care easier to access, especially for patients looking for an alternative to injectable therapies.
.jpg)
.jpg)
